Refine by
Human Cancer Articles & Analysis
58 news found
Health regulatory authorities consider this new bacterial reverse mutation test to be the gold standard for predicting a substance's potential to cause cancer in humans. It is highly sensitive and can detect suitable mutants in a wide range of bacteria. ...
BySTEMart
This versatile technology for automated data analysis facilitates retrospective and prospective human tissue studies. It is a practical and effective tool for high-throughput molecular analysis of tissues, helping to identify new diagnostic and prognostic markers and targets for human cancers, with a wide range of potential applications in basic ...
"We are finally at a stage to evaluate a computationally designed antibody in humans. Through our work with Aulos Bioscience, the first computer-designed antibody in history will be administered to human patients." "Our AI platform basically mimics the human immune system using AI," said Ofran. "For this program, we chose the IL-2 pathway, ...
Emerging trends in the biopharma industry include new developments in cancer treatments, advances in gene therapy, and more data-driven decision-making. ...
About SeqOne Genomics SeqOne Genomics offers high-performance genomic analysis solutions for healthcare providers treating patients suffering from cancer, rare and hereditary diseases as well as pharmaceutical companies developing new therapies. ...
“The 52.4% ORR from the TORCH-2 study with ATG-008 and toripalimab in patients with relapsed/metastatic cervical cancer, coupled with a manageable safety profile, is an exciting result that provides a potential guide to a registration program for ATG-008. ...
The ISET® patented EC-marked platform is able to extract down to one single cancer cell of any type from 10 ml of blood, thus a tumor cell mixed with 100 million leukocytes and 50 billion erythrocytes, according to peer-reviewed published studies. ...
Extended survival and tumor shrinkage in advanced breast cancer patients who matched the immunotherapy HLA types, lead to the development of BriaCell’s prostate cancer program based on the patient’s HLA type. ...
This data will be made available to other researchers who may find it useful for their cancer research as well as other applications.” Dr. Jennifer Willcox, PI of the UC Davis VACCS trial site noticed how many owners had interest in the potential human implications for the trial. “One remarkable experience for me was how many of the owners were ...
ByCalviri
(NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced positive Phase 1 results from its HB-200 program evaluating single-vector HB-201 and alternating 2-vector HB-202/HB-201 in advanced Human Papillomavirus 16-positive (HPV16+) head and neck cancer patients. ...
Phase 1 data show single-vector HB-201 and 2-vector HB-202/HB-201 were generally well tolerated, rapidly induced tumor-specific T cells and showed anti-tumor activity in heavily pre-treated head and neck cancer patients Poster presentation to include data supporting recommended Phase 2 dose for alternating 2-vector HB-202/HB-201 and Phase 2 development plans in head and neck ...
(OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in treating esophageal cancer (conducted at the Mayo Clinic and published last August) and FDA approval to commence a clinical trial of the Biostage Esophageal Implant, or BEI, for severe esophageal disease including ...
(OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful first-in-human experience in treating esophageal cancer (conducted at the Mayo Clinic and published last August) and FDA approval to commence a clinical trial of the Biostage Esophageal Implant for severe esophageal disease including cancer, today ...
Debiopharm is an experienced investor in the digital health domain with a special focus on cancer. Tanja Dowe, CEO of Debiopharm Innovation Fund: “We are convinced that digital solutions can fill many critical gaps in healthcare and, especially with regards to cancer therapy support, provide tremendous relief for patients and attending physicians alike. ...
(OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful first-in-human experience in treating esophageal cancer (conducted at the Mayo Clinic and published last August) and FDA approval to commence a clinical trial of the Biostage Esophageal Implant for severe esophageal disease including cancer, today ...
(OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful "first-in-human" experience in treating esophageal cancer (conducted at the Mayo Clinic and published last August) and FDA approval to commence a clinical trial of the Biostage Esophageal Implant for severe esophageal disease including cancer, today ...
The Cancer Registry of Norway is one of the oldest and most respected organisations of its kind in the world. ...
Although immunotherapy is a true breakthrough in cancer treatment and is now approved for use in more than 20 different human cancers, most patients unfortunately do not respond. If pharmacologic inhibition of PP2A significantly enhances immunotherapy of even a few human cancers, it will be a game-changer. ...
Following technology transfer, the team will create a new product by combining the two formulations, beginning with human islets. Thereafter, the team will complete preclinical studies to demonstrate the product’s characteristics in vivo, with a plan to move forward with first-in-human testing. ...
(OTCQB: BSTG) ("Biostage" or the "Company"), a biotechnology company with successful "first-in-human" experience in esophageal cancer and FDA approval to commence a clinical trial of its Biostage Esophageal Implant for esophageal disease, today announced the publication of paper establishing the basis for using its product to treat birth defects in the esophagus ...